Immunologic Factor
cixutumumab
[ sik-syoo-too-myoo-mab ]
Definitions related to cixutumumab:
-
A fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Cixutumumab selectively binds to membrane-bound IGF-1R, thereby preventing the binding of the natural ligand IGF-1 and the subsequent activation of PI3K/AKT signaling pathway. Downregulation of the PI3K/AKT survival pathway may result in the induction of cancer cell apoptosis and may decrease cancer cellular proliferation. IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily overexpressed by many cancer cell types, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been implicated in tumorigenesis and metastasis.NCI ThesaurusU.S. National Cancer Institute, 2021
-
A substance being studied in the treatment of some types of cancer. It is a monoclonal antibody that is made in the laboratory and can bind to substances in the body. Cixutumumab blocks the action of a protein needed for cell growth and may kill cancer cells. It is a type of insulin-like growth factor-1 receptor (IGF-1R) inhibitor.NCI Dictionary of Cancer TermsU.S. National Cancer Institute, 2021
Return to OpenMD Medical Dictionary
> C
This content should not be used in place of medically-reviewed decision support reference material or professional medical advice. Some terms may have alternate or updated definitions not reflected in this set. The definitions on this page should not be considered complete or up to date.